Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive, multi-organ lipid storage disease.
• Clinical onset typically occurs in infancy or the first two decades, with infantile diarrhea as a potential early sign.
• Key features include juvenile cataracts, tendon xanthomas, progressive neurological deficits, osteoporosis, cardiac issues, and premature arteriosclerosis.

Purpose of the Study:

• To review the key aspects of Cerebrotendinous xanthomatosis (CTX).
• To highlight the genetic basis and metabolic pathways involved in CTX.
• To emphasize the importance of early diagnosis and treatment for this preventable inborn error of metabolism.

Main Methods:

• Review of existing literature on CTX.
• Analysis of the genetic mutations in the sterol 27 hydroxylase gene (CYP27).
• Discussion of the biochemical consequences of CYP27 mutations, including bile acid synthesis defects and lipid accumulation.

Main Results:

• CTX results from mutations in the CYP27 gene, impairing cholesterol conversion to bile acids.
• Reduced bile acid synthesis leads to failed feedback inhibition of cholesterol production, elevated serum cholestanol, and urinary bile alcohols.
• Early intervention with chenodeoxycholic acid (CDCA) is effective in preventing clinical manifestations and disease progression.

Conclusions:

• CTX is a potentially under-diagnosed, fatal inborn error of metabolism.
• Genetic variations in CYP27 cause CTX, leading to characteristic lipid deposition.
• Prompt recognition and treatment with CDCA are crucial for managing CTX and preventing severe outcomes.